PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33992804-3 2021 Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-71 33992804-3 2021 Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 73-78 31915059-0 2020 Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Simvastatin 0-6 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 20-25 33554328-3 2021 Recently, simvastatin, a 3-hydroxy-3-methylyglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, is being evaluated for vitiligo management because of its multimodal action, easy availability, and low cost. Simvastatin 10-21 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 65-83 32068819-2 2020 Objective: To evaluate the association of genetically proxied inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (ie, genetic variants related to lower function of HMG-CoA reductase, target of statins) with epithelial ovarian cancer among the general population and in BRCA1/2 mutation carriers. Simvastatin 214-221 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 76-133 32068819-2 2020 Objective: To evaluate the association of genetically proxied inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (ie, genetic variants related to lower function of HMG-CoA reductase, target of statins) with epithelial ovarian cancer among the general population and in BRCA1/2 mutation carriers. Simvastatin 214-221 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 185-202 31915059-1 2020 OBJECTIVE: To describe successful therapeutic strategies in statin-induced anti-HMGCR myopathy. Simvastatin 60-66 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 80-85 31915059-2 2020 METHODS: Retrospective data from a cohort of 55 patients with statin-induced anti-HMGCR myopathy, sequentially stratified by the presence of proximal weakness, early remission, and corticosteroid and IVIG use at treatment induction, were analyzed for optimal successful induction and maintenance of remission strategies. Simvastatin 62-68 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 82-87 32042518-0 2020 Self-reported Morisky Eight-item Medication Adherence Scale for Statins Concords with the Pill Count Method and Correlates with Serum Lipid Profile Parameters and Serum HMGCoA Reductase Levels. Simvastatin 64-71 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 169-185 31861911-4 2019 Very rarely, statins induce an anti-HMGCR positive immune-mediated necrotizing myopathy. Simvastatin 13-20 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-41 31791994-0 2019 Statin-induced anti-HMGCR antibody-related immune-mediated necrotising myositis achieving complete remission with rituximab. Simvastatin 0-6 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 20-25 30106444-5 2018 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor of the mevalonate pathway that inhibits YAP bioactivity through nuclear translocation and total YAP expression, increased the cytotoxicity of EGFR inhibitors (cetuximab and gefitinib) against CRC cells. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-72 31737505-3 2019 Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway. Simvastatin 0-7 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-56 31737505-3 2019 Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway. Simvastatin 0-7 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-63 30833076-3 2019 Simvastatin, a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor, was found to exhibit therapeutic effects against many types of cancers including breast cancer, colon cancer, lung cancer, etc. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-73 30255302-3 2019 In this context, the aim of this study was to assess the influence of simvastatin, a leading member of the family of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known to display anti-inflammatory and immunomodulatory activity, on symptoms and lung function, as well as the proportion of inflammatory cells, cytokines, proteolytic enzymes, and surfactant protein D (SP-D) content in bronchoalveolar lavage fluid (BALF) in COPD patients. Simvastatin 70-81 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 117-174 30563555-4 2018 Simvastatin, a HMG-CoA reductase enzyme inhibitor has been shown to have pleiotropic anti-inflammatory effects as well as being endothelial protective. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-32 30089652-8 2018 We observed that the decrease in AR may occur through simvastatin-mediated inhibition of the mTOR pathway, whose activation was associated with increased HMGCR and AR expression. Simvastatin 54-65 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 154-159 30015955-2 2018 Simvastatin is a statins that is able to competitively inhibit the activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 79-126 28930754-1 2017 BACKGROUND/AIMS: The 3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMG-CoA) reductase inhibitor simvastatin has been shown to trigger apoptosis of several cell types. Simvastatin 90-101 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 21-79 28928655-1 2017 Simvastatin is a lipid-lowering agent that blocks the production of cholesterol through inhibition of 3-hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 102-158 27513191-2 2017 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor that crosses the blood-brain barrier, has been proposed for the treatment of SLOS based on in vitro and in vivo studies suggesting that simvastatin increases the expression of hypomorphic DHCR7 alleles. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-62 27513191-2 2017 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor that crosses the blood-brain barrier, has been proposed for the treatment of SLOS based on in vitro and in vivo studies suggesting that simvastatin increases the expression of hypomorphic DHCR7 alleles. Simvastatin 209-220 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-62 32095453-1 2017 Simvastatin is used to reduce plasma cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and is primarily used to treat hypercholesterolemia. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-120 26319048-2 2016 We have previously shown that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin directly inhibits ABCB1, alters the glycosylation of the transporter, and enhances the intracellular accumulation of doxorubicin with subsequent anti-cancer action. Simvastatin 102-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-91 27470565-1 2016 Simvastatin,a 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor, is clinically used in the prevention and treatment of cardiovascular diseases. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-64 27335167-7 2016 The inhibitory effect of simvastatin on atrial fibroblasts was abrogated by mevalonic acid (500 muM) that bypasses 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibition. Simvastatin 25-36 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 115-172 26761203-2 2016 Notably, statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors whose pleiotropic effects include disrupting small GTPase activity; therefore, we hypothesized the statin simvastatin could be used to attenuate RhoA activity and inhibit the deleterious effects of increased age-related matrix stiffness on endothelial barrier function. Simvastatin 196-207 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 21-78 26502771-6 2016 Within 2 weeks of taking simvastatin, a 3-hydroxy-3-methylglutaryl CoA reductase (statin) therapy, the patient redeveloped fatigue, jaundice, and cholestatic hepatitis. Simvastatin 25-36 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 40-80 27042994-1 2016 Simvastatin is a cholesterol-lowering drug, inhibiting 3-hydroxy-3-methylglutaryl-coenzyme CoA (HMG-CoA) reductase. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-114 26277021-1 2015 PURPOSE: We investigated the synergistic effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor plus radiation therapy, on the proliferation and survival of gastric cancer (GC) and colorectal cancer (CRC) cells. Simvastatin 51-62 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 66-113 25982544-0 2015 Evaluating early administration of the hydroxymethylglutaryl-CoA reductase inhibitor simvastatin in the prevention and treatment of delirium in critically ill ventilated patients (MoDUS trial): study protocol for a randomized controlled trial. Simvastatin 85-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 39-74 25122066-6 2014 Combination of simvastatin and metformin decreased Akt Ser-473 and Thr-308 phosphorylation and AMPKalpha Ser-485/491 phosphorylation; increased Thr-172 phosphorylation and AMPKalpha activity, as assessed by increased Ser-79 and Ser-872 phosphorylation of acetyl-CoA carboxylase and HMG-CoAR, respectively; decreased HMG-CoAR activity; and reduced total cellular cholesterol and its synthesis in both cell lines. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 282-290 25901147-4 2015 The galacotsylated albumin nanoparticles were prepared for the selective delivery of a Simvastatin to the 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) the rate-limiting enzyme in the pathway of cholesterol biosynthesis that is particularly presents on hepatocytes. Simvastatin 87-98 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 106-172 25453767-5 2015 Among HMG-CoA reductase inhibitors, simvastatin-treatment was less effective in terms of spike frequency as compared with atorvastatin- and rosuvastatin-treated animals. Simvastatin 36-47 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 6-23 25311809-5 2014 Inhibition of 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme of the mevalonate pathway, by lipophilic statins such as simvastatin and atorvastatin resulted in a specific inhibition of B cell activation via CD40 and impaired their ability to act as stimulatory APCs for allospecific T cells. Simvastatin 138-149 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-54 25122066-6 2014 Combination of simvastatin and metformin decreased Akt Ser-473 and Thr-308 phosphorylation and AMPKalpha Ser-485/491 phosphorylation; increased Thr-172 phosphorylation and AMPKalpha activity, as assessed by increased Ser-79 and Ser-872 phosphorylation of acetyl-CoA carboxylase and HMG-CoAR, respectively; decreased HMG-CoAR activity; and reduced total cellular cholesterol and its synthesis in both cell lines. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 316-324 23846804-0 2013 HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages. Simvastatin 30-41 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 24806822-1 2014 Simvastatin (SV), a drug of the statin class currently used orally as an anti-cholesterolemic via the inhibition of the 3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMG-CoA) reductase, has been found not only to reduce cholesterol but also to have several other pharmacological actions that might be beneficial in airway inflammatory diseases. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 120-178 24666612-11 2014 HMGCR activity was significantly decreased up to 50% and 70% at 50 muM and 75 muM of Simvastatin respectively compared to the vehicle control in C4-2 cells. Simvastatin 85-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-5 24666612-15 2014 CONCLUSION: The inhibition of HMGCR via Simvastatin lowered the viability of castration-resistant C4-2 cells. Simvastatin 40-51 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-35 23541442-7 2013 Importantly, the HMG-coA reductase inhibitor simvastatin attenuated IL-18-induced TRAF3IP2 induction. Simvastatin 45-56 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 17-34 22985805-0 2012 Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial. Simvastatin 52-63 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-35 23256625-2 2013 This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. Simvastatin 131-142 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 102-119 23386644-7 2013 Simvastatin inhibited cholesterol biosynthesis and enzyme activity but increased HMGCR mRNA and protein expression. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 81-86 23386644-8 2013 Resveratrol potentiated the inhibitory effects of simvastatin on cholesterol biosynthesis and HMGCR enzyme activity and abrogated the stimulatory effects of simvastatin on HMGCR mRNA transcripts and protein expression. Simvastatin 50-61 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 94-99 23386644-8 2013 Resveratrol potentiated the inhibitory effects of simvastatin on cholesterol biosynthesis and HMGCR enzyme activity and abrogated the stimulatory effects of simvastatin on HMGCR mRNA transcripts and protein expression. Simvastatin 157-168 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 172-177 23817018-3 2013 Simvastatin (Sim), a 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor, has been previously reported to inhibit EMT in human proximal tubular epithelial cells and porcine lens epithelial cells and to suppress Smad2/3 phosphorylation in animal models. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 21-71 23817018-3 2013 Simvastatin (Sim), a 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor, has been previously reported to inhibit EMT in human proximal tubular epithelial cells and porcine lens epithelial cells and to suppress Smad2/3 phosphorylation in animal models. Simvastatin 0-3 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 21-71 29403775-1 2012 Simvastatin (SIM) is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor widely used in hyperlipidemia therapy. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 23-70 29403775-1 2012 Simvastatin (SIM) is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor widely used in hyperlipidemia therapy. Simvastatin 13-16 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 23-70 22658637-12 2012 CONCLUSIONS: Our findings suggested that simvastatin counteracted the stimulatory effect of TNF-alpha on secretion and expression of MCP-1, PAI-1 and adiponectin, implying a potential anti-atherogenic effect during the inflammatory process; these pleitropic effects were more pronounced with HMG-CoA reductase inhibitor. Simvastatin 41-52 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 292-309 22985805-3 2012 The Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial is a multicenter, prospective, randomized, allocation concealed, double-blind, placebo-controlled clinical trial which aims to test the hypothesis that treatment with simvastatin will improve clinical outcomes in patients with ALI. Simvastatin 56-67 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-39 22985805-3 2012 The Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial is a multicenter, prospective, randomized, allocation concealed, double-blind, placebo-controlled clinical trial which aims to test the hypothesis that treatment with simvastatin will improve clinical outcomes in patients with ALI. Simvastatin 303-314 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-39 21871960-1 2012 The role of autophagy, a process in which the cell self-digests its own components, was investigated in glioma cell death induced by the hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase-inhibiting drug simvastatin. Simvastatin 206-217 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 137-189 22541079-1 2012 To investigate the effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (SV) on proliferation, apoptosis and the PI3K/AKT signaling pathway in human acute monocytic leukemia cell line SHI-1. Simvastatin 88-99 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-77 22761797-8 2012 Treatment with cholesterol-lowering simvastatin induced up to 90% reduction in relative cell number of normal cell lines but a 15-20% reduction in relative number of cancer cells, an effect accompanied by sharp upregulation of HMGCR and LDLR. Simvastatin 36-47 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 227-232 20473500-0 2011 HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients. Simvastatin 28-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 20473500-1 2011 To investigate whether anti-inflammatory effects of HMG-CoA reductase inhibitor simvastatin (SMV) in rheumatoid arthritis (RA) is mediated by Toll-like receptor-2 (TLR-2) signal via inhibiting activation of RhoA, a small Rho GTPase that plays an important role in inflammatory responses. Simvastatin 80-91 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-69 20473500-1 2011 To investigate whether anti-inflammatory effects of HMG-CoA reductase inhibitor simvastatin (SMV) in rheumatoid arthritis (RA) is mediated by Toll-like receptor-2 (TLR-2) signal via inhibiting activation of RhoA, a small Rho GTPase that plays an important role in inflammatory responses. Simvastatin 93-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-69 21864337-5 2011 METHODS: We used simvastatin (1-15 muM) to inhibit 3-hydroxy-3-methlyglutaryl-coenzyme A (HMG-CoA) reductase which converts HMG-CoA to mevalonate. Simvastatin 17-28 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 51-108 20467885-1 2011 Simvastatin, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) is known to stimulate apoptotic cell death and induce cell cycle arrest through inhibition of proteasome. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 35-82 20467885-1 2011 Simvastatin, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) is known to stimulate apoptotic cell death and induce cell cycle arrest through inhibition of proteasome. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 84-91 21417623-7 2011 CONCLUSION: We identified lipidomic biomarkers of simvastatin treatment effect that are consistent with statin inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase (ClinicalTrials.gov: NCT00935259). Simvastatin 50-61 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 125-183 21206971-2 2011 It has been suggested that the 3-hydroxy-3-methyl-glutarylcoenzyme-CoA (HMG-CoA) reductase inhibitor simvastatin exhibits anticancer properties. Simvastatin 101-112 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-90 20177788-9 2010 Twenty-two patients were started on 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (atorvastatin or simvastatin). Simvastatin 122-133 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-93 22216116-11 2011 Both statins, hydrophilic pravastatin and hypdrophobic simvastatin caused redistribution of OATP1B1 and HMGCR to perinuclear sites. Simvastatin 55-66 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 104-109 20512931-1 2010 We previously identified the marked upregulation of integrin beta4 in human lung endothelial cells (EC) treated with simvastatin, an HMG coA-reductase inhibitor with vascular-protective and anti-inflammatory properties in murine models of acute lung injury (ALI). Simvastatin 117-128 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 133-150 20878096-2 2010 Simvastatin is a cholesterol-lowering drug which inhibits 3-hydroxy-3-methylglutarylcoenzyme CoA (HMG-CoA) reductase. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-116 20413733-0 2010 Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Simvastatin 86-97 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-36 19816600-11 2009 The observation that simvastatin inhibited the apoptosis of HG-treated LECs in its therapeutic concentration suggests that daily dosage of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used by diabetic patients may increase PCO formation. Simvastatin 21-32 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 139-196 18485137-1 2008 Simvastatin is an agent of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor group of drugs. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-78 20005478-3 2009 Using a panel of immortalized lymphocyte cell lines incubated with simvastatin, we recently found that the magnitude of expression of an alternatively spliced HMGCR transcript lacking exon 13 was inversely correlated with in vivo reductions of total cholesterol, low-density lipoprotein cholesterol, apoB, and triglycerides after statin treatment of the individuals from whom the cells were derived. Simvastatin 67-78 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 159-164 19211998-1 2008 Our goal was to analyze the effects of treatment with a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (simvastatin, 40 mg/day) on serum S100BB and tau protein levels during the acute ischemic stroke (IS). Simvastatin 125-136 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 56-113 18625202-0 2008 HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Simvastatin 28-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 18625202-1 2008 Simvastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway required for the biosynthesis of cholesterol and higher isoprenoids such as geranylgeranyl pyrophosphate (GGPP). Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-59 18679777-6 2008 We have concluded that simvastatin-induced PC3 cells apoptosis is dependent on 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibition and independent of MPT, whereas necrosis is dependent on mitochondrial dysfunction caused, at least in part, by calcineurin. Simvastatin 23-34 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 79-126 18463201-3 2008 To induce NF-kappaB, we took into account the effect of doxorubicin itself and of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin; as NF-kappaB inhibitors, we chose the sesquiterpene lactones parthenolide and artemisinin. Simvastatin 144-155 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 86-133 18559695-3 2008 METHODS AND RESULTS: We measured mRNA expression of both the full-length and the alternatively spliced HMGCR transcript lacking exon 13 (HMGCRv_1) in 170 simvastatin-incubated immortalized lymphocyte cell lines derived from participants in the Cholesterol and Pharmacogenetics (CAP) study who were treated with simvastatin 40 mg/d for 6 weeks. Simvastatin 154-165 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-108 18383345-4 2008 To assess the functional importance of the sterol synthesis pathway to adult human glial progenitors, we used simvastatin or pravastatin to inhibit HMG-CoA reductase, and then assessed the phenotypic differentiation of the progenitors, as well as the molecular concomitants thereof. Simvastatin 110-121 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 148-165 18375239-5 2008 Simvastatin is representative of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) class of lipid-altering drugs, which are the most effective agents for lowering LDL cholesterol levels and also have modest benefits in raising HDL cholesterol and lowering TG levels. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-84 18453621-7 2008 This effect was reversed by mevalonic acid, a downstream metabolite of 3-hydroxy-3-methylglutaryl CoA reductase, confirming that simvastatin"s specific effect is through the inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase. Simvastatin 129-140 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 71-111 17980884-1 2008 OBJECTIVE: The combination of simvastatin, an HMG-CoA reductase inhibitor, and ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesterol synthesis and absorption and reduces circulating LDL-cholesterol concentrations. Simvastatin 30-41 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 46-63 17980884-8 2008 Simvastatin and the combination of ezetimibe and simvastatin increased the HMG-CoA reductase and LDLR gene expression while ezetimibe had no effect. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 75-92 17980884-8 2008 Simvastatin and the combination of ezetimibe and simvastatin increased the HMG-CoA reductase and LDLR gene expression while ezetimibe had no effect. Simvastatin 49-60 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 75-92 18332269-10 2008 CONCLUSIONS: HMGCR gene polymorphisms are associated with reduced plasma LDL-C and LDL-C response to simvastatin, and these effects are most evident in blacks. Simvastatin 101-112 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 13-18 18270459-0 2008 HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia. Simvastatin 29-40 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 17655704-5 2007 Intrapatient (cycles I/II vs. III/IV) and interpatient comparison (vs. ten patients without simvastatin) showed reduction of drug resistance by inhibition of HMG-CoA-reductase. Simvastatin 92-103 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 158-175 17928568-0 2008 HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer"s disease patients independently of cholesterol-lowering effects. Simvastatin 28-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 17870053-0 2007 Effect of ScrF I polymorphism in the 2nd intron of the HMGCR gene on lipid-lowering response to simvastatin in Chinese diabetic patients. Simvastatin 96-107 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-60 17716606-11 2007 In conclusion, this study shows clearly that TNF-alpha and IL-1beta are harmful to early EPC and that the HMG-CoA reductase inhibitor simvastatin protects EPC from TNF-alpha- and eventually from IL-1beta-mediated apoptosis. Simvastatin 134-145 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 106-123 17901590-4 2007 The aim of the present study was to analyze: 1) the impact of HMG-CoAR inhibitor, simvastatin, on human BA cell growth and 2) effect of simvastatin on apoptosis related proteins Bax/Bcl-2 and cyclooxygenase-2. Simvastatin 82-93 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 62-70 16774905-0 2006 HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation. Simvastatin 28-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 17251484-1 2007 PURPOSE: Results in a prior study have demonstrated that systemic administration of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor simvastatin to healthy subjects reduces intraocular pressure and increases retinal blood flow. Simvastatin 156-167 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 88-145 16321621-1 2005 OBJECTIVE: Our objective was to investigate the interactions between common polymorphisms in ABCB1, CYP3A4, and CYP3A5 genes and the lipid-lowering efficacy and safety of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin. Simvastatin 233-244 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 175-222 16450390-2 2006 Mevastatin and simvastatin, 2 inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase, potentiated the intracellular accumulation and the cytotoxicity of doxorubicin in HMM cells constitutively expressing P-glycoprotein and multidrug resistance-associated protein 3. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 44-100 16778328-5 2006 Interestingly, the improvement of %FMD by treatment with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (simvastatin) was greater in the group showing a decrease in FasL mRNA than in the group with no such decrease. Simvastatin 118-129 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 59-106 16550313-1 2006 Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has long been thought to exert its benefits by reducing cholesterol synthesis, and has been shown to significantly reduce cardiovascular events and mortality in patients with or without coronary artery disease. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-72 16188573-1 2005 Simvastatin, a widely used 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor, effectively reduced cardiac death and ischemic events in patients with coronary heart disease (CHD) and diabetes mellitus (DM). Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-77 15781755-3 2005 METHODS AND RESULTS: Competitive reverse transcription-polymerase chain reaction analysis and flow cytometry showed that simvastatin, an HMG-CoA reductase inhibitor, dose-dependently reduced monocyte CCR2 mRNA and protein expression. Simvastatin 121-132 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 137-154 15677772-1 2005 Simvastatin is best known for its antilipidemic action and use in cardiovascular disease due to its inhibition of 3-hydroxy-3-methylglutaryl CoenzymeA (HMG CoA) reductase, a key enzyme in the cholesterol synthesis pathway. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 114-170 16185099-5 2005 In some of these trials (such as 4S [Scandinavian Simvastatin Survival Study], CARE [Cholesterol and Recurrent Events] trial, and the HPS [Heart Protection Study]), HMG-CoA reductase inhibitor treatment significantly reduced cardiovascular events in diabetic patients, whereas in other trials (ALLHAT-LLT [Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial], ASCOT [Anglo-Scandinavian Cardiac Outcomes Trial]) the reductions were not significant. Simvastatin 50-61 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 165-182 16327254-2 2005 HMG-CoA reductase inhibitor drugs or statins (simvastatin, atorvastatin, pravastatin) reduce the relative risk of IS by between 18 and 51% in patients with IHD, in patients with high vascular disease risk and in hypertensive patients with other RFs, acute coronary syndrome, and type 2 diabetes mellitus. Simvastatin 46-57 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 15531380-1 2004 Pharmacokinetic and pharmacodynamic interactions between simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, and diltiazem, a calcium antagonist, were investigated in 7 male and 4 female patients with hypercholesterolemia and hypertension. Simvastatin 57-68 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 72-129 15531380-7 2004 These apparent pharmacokinetic interactions, namely the increase of HMG-CoA reductase inhibitor concentration by diltiazem and the decrease of diltiazem concentration by simvastatin, enhance the cholesterol-lowering effects of simvastatin during combined treatment. Simvastatin 227-238 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 68-85 15571475-1 2004 Simvastatin is a long-established hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, first introduced in 1988. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-87 15161667-0 2004 The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Simvastatin 32-43 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-21 15194586-10 2004 CONCLUSIONS: Our data show that simvastatin, by blocking HMGCoA-reductase and interfering in the prenylation processes, is able to inhibit MMP-3 production from cultured human chondrocytes that have been either unstimulated or stimulated with IL1beta, thus suggesting a possible additional mechanism for statins in counteracting chronic joint disease related cartilage damage. Simvastatin 32-43 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-73 15339992-8 2004 EC proliferation and cell cycle progression, examined by 5,6-carboxyfluorescein diacetate succinimidyl ester staining, demonstrated that anti-HLA-induced EC proliferation was efficiently prevented by the 3-hydroxy-3-methylglutaryl CoA reductase inhibitor simvastatin (0.1 micromol/L) through inhibition of RhoA geranylgeranylation. Simvastatin 255-266 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 204-244 12805493-9 2003 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin inhibited the PTHrP(1-36) induction of both NF-kappaB activity and MCP-1 overexpression, and this was reversed by mevalonate. Simvastatin 62-73 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-51 15069546-1 2004 To look for new candidates for agents to use in maintenance therapy for myeloma patients, the growth inhibitory effects of a 3-hydroxy-3-mehtylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin), simvastatin, was analyzed using human myeloma cell lines. Simvastatin 203-214 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 125-182 14512881-2 2003 The present study was aimed to study the changes induced on bile acid synthesis by simvastatin, a competitive inhibitor of hydroxymethyl glutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme of cholesterol synthesis, during pharmacologic interruption of the enterohepatic circulation. Simvastatin 83-94 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 123-169 12960612-3 2003 We show here that two different 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), atorvastatin and simvastatin, strongly increase the expression and functional activity of TM in human umbilical vein endothelial cells, human coronary artery endothelial cells, and EA.hy926 endothelial cells. Simvastatin 119-130 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 32-79 12867249-2 2003 The latest landmark trial of therapy using a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) is the Heart Protection Study (HPS) of simvastatin versus placebo in a cohort of patients at high risk for CAD. Simvastatin 151-162 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 45-92 12841814-1 2003 OBJECTIVE: To report a case of rhabdomyolysis after concomitant use of simvastatin, a commonly used hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, and fluconazole, an azole antifungal agent. Simvastatin 71-82 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 100-152 12753293-4 2003 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, on the expression of t-PA, PAI-1 and tissue factor after activation of the cells with tumor necrosis factor-alpha (TNF-alpha). Simvastatin 128-139 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 59-116 14755972-2 2003 In our study, from HMG-CoA reductase"s known inhibitors, we used simvastatin (ZOCOR), which is a semi synthetic derivative of the second generation. Simvastatin 78-83 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 19-36 12671581-1 2003 INTRODUCTION: Simvastatin is a competitive inhibitor of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase which is effective in the treatment of various hyperlipidemia. Simvastatin 14-25 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-117 12856828-1 2003 Simvastatin is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-determining enzyme for cholesterol synthesis which is used in the treatment of hypercholesterolemias, particularly in type IIa and IIb hyperlipoproteinemias, frequently in postmenopausal women. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-99 14755972-2 2003 In our study, from HMG-CoA reductase"s known inhibitors, we used simvastatin (ZOCOR), which is a semi synthetic derivative of the second generation. Simvastatin 65-76 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 19-36 11753267-2 2001 The effects of St John"s Wort on the pharmacokinetics of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors simvastatin (an inactive lactone pro-drug) and pravastatin were determined in this study. Simvastatin 116-127 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-104 12371961-3 2002 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, simvastatin, on the expression of t-PA and PAI-1. Simvastatin 118-129 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 59-106 12386648-1 2002 Simvastatin, a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, is a commonly used cholesterol-lowering agent. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-67 12096273-13 2002 The ancillary properties of 3-Hydroxy-3 methylglutaryl CoA reductase inhibitors typified by simvastatin may be important in this regard. Simvastatin 92-103 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-68 12017409-2 2002 OBJECTIVE: The goal of this study was to develop a preliminary pharmacodynamic model for dosing of the hydroxymethylglutaryl coenzyme A (HMG-CoA)-reductase inhibitors simvastatin and atorvastatin using neural network analysis. Simvastatin 167-178 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-155 11914545-4 2002 As shown in this study, simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the key enzyme for cholesterol biosynthesis, is able to prevent these events following the expression of the transforming Ha-ras oncogene. Simvastatin 24-35 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 53-110 11550401-1 2001 Simvastatin, a hydroxymethyl glutarate coenzyme A (HMG-CoA) reductase inhibitor, is a commonly used cholesterol lowering agent. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-69 11716837-3 2001 On the other hand, the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor simvastatin reduced both cholesterol and squalene synthesis from [14C]acetate. Simvastatin 80-91 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 23-69 11397960-2 2001 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors, e.g., simvastatin, have been shown to reduce the incidence of graft vascular disease. Simvastatin 65-76 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-46 11282095-4 2001 Serum cholestanol concentrations were decreased with the HMG-CoA reductase inhibitor simvastatin alone and greater reductions were achieved after the addition of the bile acid chenodeoxycholic acid; suggesting a synergistic effect of this combination. Simvastatin 85-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-74 11348878-2 2001 Here, we show that simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, within the therapeutic range (0.01 to 1 micromol/L) prevented the downregulation of eNOS mRNA and protein promoted by nLDL (180 mg cholesterol/dL, 48 hours) in human umbilical vein endothelial cells. Simvastatin 19-30 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-81 11469968-9 2001 Administration of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (simvastatin or pravastatin, 20 mg/d) should be limited to hypercholesterolemic patients with mild chronic cholestatic liver diseases in whom HDL serum levels are below the protective range or if additional risk factors for cardiovascular diseases are present. Simvastatin 88-99 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 18-75 11162604-1 2001 The cholesterol-lowering drug, simvastatin, is a pro-drug of a potent 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and inhibits cholesterol synthesis in humans and animals. Simvastatin 31-42 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-127 11318529-5 2001 Fibrate derivatives were predominantly fenofibrate, HMG-CoA reductase inhibitors were simvastatin and pravastatin. Simvastatin 86-97 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-69 11244205-5 2001 Studies conducted on the prevention of ischemic heart disease (IHD) with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), using pravastatin and simvastatin, unequivocally show reductions in overall mortality, cardiovascular mortality, acute myocardial infarction and other coronary events. Simvastatin 165-176 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 73-120 14728043-6 2001 Combination therapy with colesevelam plus hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (lovastatin, simvastatin or atorvastatin) was associated with additive reductions in serum levels of LDL-cholesterol and total cholesterol, relative to either agent alone. Simvastatin 119-130 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-94 11336576-1 2001 Simvastatin (Zocortrade mark, Merck) is a safe and effective 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 61-118 11074211-1 2000 The purpose of this study was to determine if long-term use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (atorvastatin, fluvastatin, lovastatin, pravastatin, or simvastatin) resulted in tachyphylaxis (a decreasing response to a physiologically active agent). Simvastatin 178-189 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-110 10878403-1 2000 Simvastatin belongs to a class of lipid-lowering drugs which completely inhibit 3-hydroxy-3-methylglutaryl co-enzyme A (HMG CoA) reductase. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 80-138 10946302-4 2000 We studied the effect of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, simvastatin, on cytokine-induced expression of CAMs in HUVEC. Simvastatin 86-97 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-74 10933353-2 2000 BACKGROUND: Simvastatin, an inhibitor of 3-hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase, reduced cardiovascular events in patients with myocardial infarction and hypercholesterolemia. Simvastatin 12-23 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-97 10732848-0 2000 Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography. Simvastatin 85-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 56-73 10741630-1 2000 BACKGROUND: Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase that is used as a cholesterol-lowering agent and is metabolized by cytochrome P450 3A (CYP3A) enzymes. Simvastatin 12-23 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 43-100 10620105-1 1999 Simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, is widely used to treat hyperlipidaemia. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 29-86 10583033-1 1999 AIMS: To investigate whether an interaction between diltiazem and the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin may enhance the cholesterol-lowering response to simvastatin in diltiazem-treated patients. Simvastatin 138-149 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-127 10583033-1 1999 AIMS: To investigate whether an interaction between diltiazem and the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin may enhance the cholesterol-lowering response to simvastatin in diltiazem-treated patients. Simvastatin 199-210 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-127 10365819-0 1999 Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway. Simvastatin 10-21 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 25-72 10500210-4 1999 Inhibition of the cholesterol metabolic pathway by the hydrophobic 3-hydroxy-3-methylglutaryl CoA (HMGCoA) reductase inhibitors, simvastatin and atorvastatin, reversed the effect of lipoprotein-depleted serum and up-regulated TGFbetaRII expression, whereas the hydrophilic HMGCoA reductase inhibitor, pravastatin, had no effect. Simvastatin 129-140 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 273-289 10412781-1 1999 BACKGROUND: Simvastatin, a 3-hydroxy 3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitor, is used widely for treatment of hypercholesterolemia. Simvastatin 12-23 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-85 10365819-2 1999 In the present study, the role of Ras signal transduction pathway in alpha-fetoprotein (AFP) gene expression was evaluated in HuH-7 human hepatoma cells using simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, which blocks Ras function through inhibition of farnesylation, and the ras(val-12) expression vector. Simvastatin 159-170 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 174-221 10090116-2 1999 METHODS: A validated model based on data from the Lipid Research Clinics cohort was used to estimate the benefits and cost-effectiveness of lipid modification with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) based on results from the Scandinavian Simvastatin Survival Study (4S), including a 35% decrease in low-density-lipoprotein (LDL)-cholesterol levels and an 8% increase in high-density-lipoprotein (HDL)-cholesterol levels. Simvastatin 272-283 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 164-211 10190517-1 1999 Ten years" experience of treatment with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin in 45 hypercholesterolemic high-risk patients is reported. Simvastatin 102-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 44-91 10208479-0 1999 The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Simvastatin 146-157 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 118-135 10100621-1 1999 Our previous studies have shown that the HMG-CoA reductase (HCR) inhibitor (HCRI), simvastatin, kills L6 myoblasts by involving Ca2+ mobilization from the Ca2+ pool in the cells but not by influx from extracellular space. Simvastatin 83-94 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-58 10100621-1 1999 Our previous studies have shown that the HMG-CoA reductase (HCR) inhibitor (HCRI), simvastatin, kills L6 myoblasts by involving Ca2+ mobilization from the Ca2+ pool in the cells but not by influx from extracellular space. Simvastatin 83-94 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-63 9804052-3 1998 Pharmacokinetic interaction with some of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, specifically lovastatin and simvastatin, leads to an increased incidence of muscle skeletal toxicity in transplant patients. Simvastatin 133-144 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 45-92 9728898-1 1998 OBJECTIVE: To study the effects of erythromycin and verapamil on the pharmacokinetics of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Simvastatin 89-100 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 118-165 9695968-1 1998 SCID mice were inoculated intravenously with cells from the human HL60 myeloblastic leukaemia cell line and then treated with the 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor, simvastatin, by subcutaneous continuous infusion. Simvastatin 199-210 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 130-187 9636401-0 1998 HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Simvastatin 45-56 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 9598832-7 1998 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (5 micromol/L) reduced EC accumulation derived from agLDL uptake by 58% and 35% in platelet-derived growth factor-stimulated and unstimulated VSMCs, respectively. Simvastatin 62-73 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-51 9254057-1 1997 In the monocytic THP-1 cells, the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor simvastatin (5 microM) enhances the conversion of exogenous linoleic (18:2 n-6) and eicosapentaenoic (20:5 n-3) acids to their long-chain polyunsaturated fatty acid (LC-PUFA) derivatives, and this effect is associated with changes in the desaturation steps. Simvastatin 102-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-91 9730140-1 1998 We investigated in vitro effect of simvastatin, a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on the proliferation of human and bovine endothelial cells (EC) compared to that of bovine smooth muscle cells (SMC). Simvastatin 35-46 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-114 9509899-1 1998 The recent development of specific competitive inhibitors of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase such as lovastatin, simvastatin, pravastatin and fluvastatin has provided an important new and effective approach to the treatment of hyperlipidaemia and atherosclerosis. Simvastatin 138-149 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 65-117 9258815-1 1997 We analyzed the antiproliferative effect of simvastatin (SV), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on human glioma cell lines. Simvastatin 44-55 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 78-135 9250604-3 1997 In the monocytic cells THP-1, the biosynthesis of LC-PUFA is also enhanced by treatment with the HMGCoA reductase inhibitor simvastatin (S), an effect which is reverted by mevalonate and other intermediates of cholesterol synthesis. Simvastatin 124-135 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 97-113 9160078-1 1997 Simvastatin is a potent inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase intended for use as a hypocholesterolemic agent. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-89 9220213-2 1997 The aim of this study was to investigate the safety and long-term effects on serum lipid levels of low-dose simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in Japanese patients with moderate primary hypercholesterolemia. Simvastatin 108-119 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 137-184 9027779-3 1997 Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor, reduces levels of these lipoproteins but the effect of treatment on cholesteryl ester transfer activity in patients on dialysis remains to be determined. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-72 9081681-2 1997 Reduction of plasma cholesterol levels by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin has been found to improve certain aspects of platelet function in vitro and in vivo, but controlled trials are largely lacking. Simvastatin 104-115 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 46-93 9086443-1 1997 Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and also selectively inhibits the growth of leukaemic progenitor cells. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-88 8904621-3 1996 It has been suggested that lipophilic HMG CoA reductase inhibitors, like lovastatin and simvastatin, may cause sleep disturbance. Simvastatin 88-99 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 38-55 8831932-2 1996 If HMGCoA reductase inhibitors such as simvastatin lowered LDL mainly by up-regulating LDL-receptor mediated clearance, they should decrease the overall binding affinity of LDL from an FDB heterozygote by selectively decreasing LDL bearing normal apo B. Simvastatin 39-50 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 3-19 8820110-7 1996 When incubating HepG2 cells for 16 h with the HMG-CoA reductase inhibitor simvastatin (10(-6)-10(-10) M) HMG-CoA reductase activity was increased up to 180%. Simvastatin 74-85 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 46-63 8706591-2 1996 This article discusses various aspects of cholesterol-lowering therapy using the HMG-CoA reductase inhibitor simvastatin in the light of the large Scandinavian Simvastatin Survival Study (4S). Simvastatin 109-120 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 81-98 8729584-2 1996 It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. Simvastatin 104-115 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-79 8820110-7 1996 When incubating HepG2 cells for 16 h with the HMG-CoA reductase inhibitor simvastatin (10(-6)-10(-10) M) HMG-CoA reductase activity was increased up to 180%. Simvastatin 74-85 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 105-122 8560403-6 1995 The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (20 mg/day for 2 months) significantly reduced cholesterol levels, urinary 11-dehydro-TxB2 excretion, plasma elastase and plasma F1 + 2 in 8 patients. Simvastatin 69-80 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 11-58 7575771-1 1995 The long-term efficacy and tolerability of simvastatin, a 3-hydroxy-3-methylglutaryl-co-enzyme A (HMG-CoA) reductase inhibitor, was assessed during a 24-month follow-up period in 168 elderly hypercholesterolemic patients. Simvastatin 43-54 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-116 7559927-1 1995 It has been reported that the HMG-CoA reductase inhibitor simvastatin does not always effectively lower plasma LDL. Simvastatin 58-69 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-47 8540887-0 1995 Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin. Simvastatin 86-97 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 56-73 7585842-1 1995 In this pilot study, 12 patients (6 men, 6 postmenopausal women) with hypercholesterolemia were treated with low-dose (5 mg/d) simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, for 4 weeks. Simvastatin 127-138 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 142-189 7717016-0 1995 [Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up]. Simvastatin 98-109 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-87 7878672-1 1995 Pravastatin, lovastatin, and simvastatin, drugs which lower cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, have been linked to skeletal myopathies in humans and rats. Simvastatin 29-40 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 86-143 7717016-4 1995 In a prospective, randomized and controlled trial, we investigated the effects of monotherapy with the HMG-CoA-reductase inhibitor Simvastatin in heart transplant recipients. Simvastatin 131-142 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-120 7930373-1 1994 Simvastatin is an inhibitor of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase, the key enzyme in the synthesis of cholesterol, recently introduced in the therapy of hypercholesterolemic patients. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-89 7811739-4 1995 In order to show that the feedback regulation mechanism for 3-hydroxy-3-methylglutaryl-coenzyme A reductase was involved in this phenomena mRNA levels were measured in human vascular endothelial cells after incubation with the vastatins for 3.5 h and for 20 h. Indeed, lovastatin and simvastatin gave rise to higher levels of HMG-CoA reductase mRNA after 20 h than after 3.5 h of incubation. Simvastatin 284-295 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-107 19489169-2 1994 It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. Simvastatin 104-115 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-79 7857367-1 1994 Twelve men and thirteen women with hypercholesterolaemia participated in a 20-week controlled cross-over trial to assess the interaction between dietary fat intake, gender and an HMGCoA reductase inhibitor, simvastatin. Simvastatin 207-218 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 179-195 8117177-1 1994 BACKGROUND: Few studies have been performed to compare fenofibrate, a second-generation fibrate, and simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Simvastatin 101-112 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 116-163 8070302-1 1994 The clinical efficacy of the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMGCoA) reductase inhibitor simvastatin in the treatment of hypercholesterolaemia in non-insulin-dependent diabetes (NIDDM), was examined in a double-blind placebo-controlled study of 6 months in 70 patients with NIDDM (age 25-70 years), of whom 57 were randomised to placebo (29 patients) or simvastatin for 6 months, following a 3-month run-in on diet. Simvastatin 97-108 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 29-86 7631993-0 1994 [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin]. Simvastatin 66-77 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-53 8366596-6 1993 20% 3) In the attempt to increase the complete dissolution rate, bedtime administration method (one time administration instead of 3 times, every day), combination therapy of UDCA and CDCA and UDCA plus simvastatin (HMG-CoA reductase inhibitor) were tried. Simvastatin 203-214 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 216-233 8264145-2 1993 We have conducted a double-blind, placebo controlled trial of the HMG CoA reductase inhibitor simvastatin in patients with the nephrotic syndrome or significant proteinuria (> 1 g/day) and hypercholesterolemia (> or = 6.5 mmol/liter). Simvastatin 94-105 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 66-83 8213497-5 1993 Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, which include lovastatin, simvastatin, and pravastatin, are the most effective of the currently available drugs and show dose-dependent effects on the concentrations of LDL cholesterol, which decrease by 20-45% in response to these drugs when used over the full dosage range. Simvastatin 99-110 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-71 8240151-0 1993 Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin. Simvastatin 89-100 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-53 8240151-1 1993 BACKGROUND: Simvastatin and pravastatin are both competitive inhibitors of the rate limiting enzyme for cholesterol biosynthesis (HMG CoA) reductase, but data from individual clinical trials suggest significant differences in potency for cholesterol reduction between the two drugs. Simvastatin 12-23 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 104-148 8510521-5 1993 In eight FCH patients, treatment with the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin resulted in significantly increased mean LPL activities and plasma Lp(a) concentrations. Simvastatin 110-121 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-99 8343198-1 1993 Simvastatin is a methyl analogue of lovastatin and acts as an HMG-CoA reductase inhibitor effective in the treatment of hypercholesterolaemia. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 62-79 7761664-3 1993 The authors treated a group of elderly patients with Simvastatin (20 mg/day for 1 year), a HMG CoA reductase inhibitor and observed a significant reduction in total cholesterol (p < 0.001). Simvastatin 53-64 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 91-108 8471404-2 1993 It has been suggested that HMG CoA reductase inhibitors which are administered as inactive, lipophilic lactones (e.g. simvastatin) have a greater propensity to evoke nocturnal sleep disturbances than pravastatin, an inhibitor given in the active, hydrophilic, open-acid form. Simvastatin 118-129 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-44 8343198-13 1993 Elevated HMG-CoA reductase inhibitory activity has been observed when simvastatin was administered concurrently with cyclosporin, possibly increasing the risk of myopathy and subsequent rhabdomyolysis which are associated with simvastatin use. Simvastatin 70-81 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 9-26 8343198-13 1993 Elevated HMG-CoA reductase inhibitory activity has been observed when simvastatin was administered concurrently with cyclosporin, possibly increasing the risk of myopathy and subsequent rhabdomyolysis which are associated with simvastatin use. Simvastatin 227-238 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 9-26 8440592-10 1993 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity in microsomal membranes from human lens cortex was inhibited by simvastatin and pravastatin to the same extent. Simvastatin 121-132 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 1488408-0 1992 Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Simvastatin 175-186 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 54-111 8442035-0 1993 HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation. Simvastatin 43-54 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-16 1643632-1 1992 The effect of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on human glioma cell growth was investigated. Simvastatin 14-25 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 43-90 1493355-4 1992 The HMG-CoA reductase inhibitors lovastatin, simvastatin and pravastatin are potent well tolerated hypolipidaemic therapies in young subjects. Simvastatin 45-56 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-21 1484945-1 1992 The effect of diet on plasma lipids and lipoproteins was examined in 19 patients with familial hypercholesterolaemia treated with the HMGCoA reductase inhibitor, simvastatin. Simvastatin 162-173 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 134-150 1394987-2 1992 We investigated the changes in serum TC concentrations obtained with simvastatin, an inhibitor of hydroxymethylglutaryl-CoA reductase, in 70 hypercholesterolemic subjects. Simvastatin 69-80 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 98-133 10146977-6 1992 Studies to date therefore suggest that therapy with HMG-CoA reductase inhibitors (i.e. lovastatin and simvastatin) is substantially more cost-effective than treatment with bile-acid sequestrants. Simvastatin 102-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-69 1418074-0 1992 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Simvastatin 58-69 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 1596304-1 1992 Fourteen women and five men participated in a 20-week controlled, cross-over trial of the interaction of simvastatin, an HMGCoA reductase inhibitor, with high and low fat diets. Simvastatin 105-116 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 121-137 1572035-7 1992 The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (20 mg/day for 6 months) significantly reduced cholesterol levels by 22-28% and urinary 11-dehydro-TXB2 excretion by 32-42% in 10 patients. Simvastatin 69-80 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 11-58 10146941-3 1992 The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor simvastatin is a well tolerated and highly effective antihyperlipidaemic agent. Simvastatin 72-83 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-61 1412144-1 1992 HMG-CoA reductase inhibitors: lovastatin and simvastatin]. Simvastatin 45-56 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 1412144-2 1992 Lovastatin and simvastatin are the first licensed compounds of a potent new class of lipid lowering drugs whose mechanism of action is to inhibit HMG-CoA reductase, a rate-limiting enzyme in the cholesterol biosynthetic pathway in the liver. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 146-163 1789813-1 1991 The 3-years efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (S) (previously called synvinolin or MK-733) has been studied in single and combined therapy with cholestyramine (C) in 48 hypercholesterolaemic patients. Simvastatin 97-108 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 39-86 1789813-1 1991 The 3-years efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (S) (previously called synvinolin or MK-733) has been studied in single and combined therapy with cholestyramine (C) in 48 hypercholesterolaemic patients. Simvastatin 132-142 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 39-86 1865167-1 1991 The long-term effects (66 weeks) of simvastatin (40 mg in one or two doses per day), an inhibitor of HMG CoA-reductase, were evaluated in 12 patients with familial dysbetalipoproteinaemia (type III hyperlipoproteinaemia). Simvastatin 36-47 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 101-118 1951069-1 1991 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, has been administered to approximately 2,400 patients with primary hypercholesterolemia with a mean follow-up of 1 year in controlled clinical studies and their open extensions. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-62 1800703-0 1991 Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. Simvastatin 198-209 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 88-145 1903069-1 1991 The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin, reduced low-density-lipoprotein (LDL) cholesterol in hypercholesterolaemic patients by 40% (P less than 0.001). Simvastatin 72-83 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-61 1832610-6 1991 The first includes inactive lactone prodrugs, as Lovastatin and Simvastatin, that are enzymatically hydrolyzed to the corresponding ring-opened active forms in the liver, where the HMGCoA reductase inhibitors must chiefly reduce cholesterol synthesis. Simvastatin 64-75 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 181-197 1832610-8 1991 Several clinical studies seem to demonstrate a greater cholesterol-lowering effect of the active form of Simvastatin, probably because of its more affinity for the HMGCoA reductase enzyme. Simvastatin 105-116 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 164-180 2047945-0 1991 A 6-month trial of simvastatin (HMG-CoA reductase inhibitor) in the treatment of hypercholesterolaemia. Simvastatin 19-30 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 32-49 2047945-1 1991 The aim of this study was to evaluate the long-term efficacy and tolerability of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor simvastatin, over a 24-week period. Simvastatin 153-164 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 85-142 1857842-1 1991 The effect of a 6-month treatment with simvastatin, an HMG CoA-reductase inhibitor, on serum lipoprotein pattern was investigated in patients affected by primary hypercholesterolemia. Simvastatin 39-50 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-72 2206035-4 1990 These drugs, including lovastatin and simvastatin, competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme of intracellular cholesterol synthesis. Simvastatin 38-49 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 73-120 1827401-1 1991 Cellular cholesterol homeostasis was examined in 11 hypercholesterolaemic Type 2 diabetic patients prior to and following reduction of serum cholesterol using simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase. Simvastatin 159-170 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 188-244 34627266-6 2021 The as-obtained Fe3O4@PCBMA-SIM nanoparticles demonstrated more cytotoxicity against MDA-MB-231 than MCF-7 due to the higher expression of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), which demonstrated that statins could effectively kill TNBC. Simvastatin 28-31 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 139-187 2224187-1 1990 Simvastatin, a pro-drug lactone, forms the open carboxylic acid as a major metabolite that inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 116-163 2167097-1 1990 A new antihypercholesterolemic drug, simvastatin (MK-733), which is a prodrug of a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, inhibited cholesterol synthesis from [14C]acetate concentration dependently without inhibiting it from [3H]mevalonate in Hep G2 cells. Simvastatin 37-48 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 90-147 2167097-1 1990 A new antihypercholesterolemic drug, simvastatin (MK-733), which is a prodrug of a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, inhibited cholesterol synthesis from [14C]acetate concentration dependently without inhibiting it from [3H]mevalonate in Hep G2 cells. Simvastatin 50-56 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 90-147 1976071-0 1990 In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Simvastatin 42-53 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 71-88 34627266-6 2021 The as-obtained Fe3O4@PCBMA-SIM nanoparticles demonstrated more cytotoxicity against MDA-MB-231 than MCF-7 due to the higher expression of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), which demonstrated that statins could effectively kill TNBC. Simvastatin 28-31 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 189-194 34627266-7 2021 Further experiments showed that SIM could inhibit the expression of HMGCR to downregulate the mevalonate (MVA) pathway and glutathione peroxidase 4 (GPX4), thereby inducing cancer cell ferroptosis. Simvastatin 32-35 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 68-73 34680049-0 2021 HMG-CoA Reductase Inhibitor, Simvastatin Is Effective in Decreasing Degree of Myocarditis by Inhibiting Metalloproteinases Activation. Simvastatin 29-40 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 34425670-6 2021 Moreover, HMGCR rs3846662 g.23092A>G was found to be homozygous (G/G) in the proband, probably leading to reduced response to simvastatin and pravastatin. Simvastatin 126-137 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 10-15 35624221-8 2022 Treatment with LCL521 or simvastatin to inhibit ASAH1 or HMGCR, respectively, resulted in accumulation of ceramide at the cell surface of PGCC and prevented PGCC progeny formation. Simvastatin 25-36 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-62 35619689-8 2022 Additionally, the overexpression of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) or 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase (HMGCR), the known target of statins, reversed the effects of simvastatin. Simvastatin 234-245 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 153-171 35619689-10 2022 Furthermore, the immunoprecipitation results confirmed the interaction between NLRP3 and HMGCR, and this interaction was inhibited by simvastatin. Simvastatin 134-145 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 89-94 35619689-11 2022 In conclusion, we demonstrated that topical application of simvastatin ointment might be a promising treatment for DNPX skin lesions and that this therapeutic effect may be related to pyroptosis inhibition via HMGCR inhibition in foam cells. Simvastatin 59-70 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 210-215 2487533-1 1989 We report the results of a two center study on the use of the HMG Co A reductase inhibitor, simvastatin, in 44 patients suffering from familial hypercholesterolemia or from primary hypercholesterolemia of unknown etiology. Simvastatin 92-103 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 62-80 2646895-1 1989 This 12-week, randomized, double-blind, multicenter study compared the efficacy, tolerability and safety of simvastatin (a potent HMG-CoA reductase inhibitor) and probucol. Simvastatin 108-119 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 130-147 3279966-1 1988 Simvastatin (MK-733), a new inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, was administered to 38 patients with heterozygous familial hypercholesterolaemia for 24 weeks. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-88 3279966-1 1988 Simvastatin (MK-733), a new inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, was administered to 38 patients with heterozygous familial hypercholesterolaemia for 24 weeks. Simvastatin 13-19 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-88 3076126-2 1988 Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-120 3076124-4 1988 The bile acid sequestrants (cholestyramine and colestipol), nicotinic acid, fenofibrate and inhibitors of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase (e.g. lovastatin or simvastatin) are the most effective drugs for use in patients with primary hypercholesterolaemia; these agents reduce plasma concentrations of total and LDL-cholesterol by 15 to 45%. Simvastatin 179-190 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 106-158 3076125-2 1988 Lovastatin (MK-803, mevinolin) and simvastatin (MK-733, synvinolin), 2 highly potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have been heralded as breakthrough therapy for the treatment of atherosclerotic disease. Simvastatin 35-46 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 85-142 3076125-2 1988 Lovastatin (MK-803, mevinolin) and simvastatin (MK-733, synvinolin), 2 highly potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have been heralded as breakthrough therapy for the treatment of atherosclerotic disease. Simvastatin 48-54 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 85-142 3076125-2 1988 Lovastatin (MK-803, mevinolin) and simvastatin (MK-733, synvinolin), 2 highly potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have been heralded as breakthrough therapy for the treatment of atherosclerotic disease. Simvastatin 56-66 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 85-142 3076125-5 1988 Lovastatin and simvastatin are the first HMG CoA reductase inhibitors to receive regulatory agency approval for marketed use. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-58 3254824-1 1988 Simvastatin (MK733), derived from lovastatin by substituting CH3 for H at the 2" position, is a potent hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-155 3254824-1 1988 Simvastatin (MK733), derived from lovastatin by substituting CH3 for H at the 2" position, is a potent hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Simvastatin 13-18 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-155